Company intelligence
Amgen
#WeareBiotech
About Amgen
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Verified activity
Signals from Amgen
42 published signals
Research & Knowledge
Amgen announced that a global Phase 3 study evaluating its DLL3-targeting therapy as a first-line maintenance treatment for people with extensive-stage small cell lung cancer met its primary endpoint.
Reported by Amgen
Research & Knowledge
Amgen published results from the GENERator team evaluating 12,026 oligonucleotides and finding regulatory elements beyond the natural comparison range.
Reported by Himanshu Jain
Research & Knowledge
Amgen published results from the DISCO team screening 90 designed genes across four reactions and reporting up to 98 percent yield in one reaction.
Reported by Himanshu Jain
Research & Knowledge
Amgen published results from OpenDDE reporting 66.4 percent interface success on its newest antibody antigen benchmark.
Reported by Himanshu Jain
Research & Knowledge
Amgen published the full study results of its research on innovative treatment approaches for small cell lung cancer.
Reported by I-Fen Chang
Research & Knowledge
Amgen published an update reflecting its continued commitment to advancing research and pursuing new possibilities for patients facing small cell lung cancer.
Reported by Jeff Warnick
Presence & Recognition
Amgen hosted Thomas Dittrich as CFO at Amgen Tampa.
Reported by Dave Dufort
People
Amgen Tampa hosted Thomas Dittrich as CFO and spent the day meeting with leadership team, Employee Resource Group representatives and employees to learn about the work happening across the site.
Reported by Dave Dufort
Research & Knowledge
Amgen published the Collibra course 'Maintain, monitor and manage data sets as a Data Owner' to provide insights into verifying privacy policies, assigning dataset responsibilities, tracking data quality issues, and managing usage requests directly within Collibra's ecosystem.
Reported by Rakesh K.
Research & Knowledge
Amgen published a new paper by Dr. Andrew Tang titled 𝘼𝙋𝙊𝙇𝙇𝙊, a multimodal temporal foundation model designed to construct virtual patient representations at healthcare system scale.
Reported by Heather Couture, PhD
People
Amgen is hiring a Senior Medical Science Liaison for the Obesity therapeutic area in AmgenUK.
Reported by Carolina Cepeda
People
Amgen is hiring a Senior Medical Advisor for the Cardiovascular therapeutic area in AmgenUK.
Reported by Carolina Cepeda
Presence & Recognition
Amgen employee Atilla Altinok participated in the PIPA Conference 2026 in Uxbridge on 9-10 September.
Reported by Atilla Altinok, PhD
People
Amgen welcomed Natalia Sennikova on September 1st as part of her new journey.
Reported by Natalia Sennikova
Presence & Recognition
Amgen is attending the European Thyroid Association’s Annual Meeting to connect with colleagues and experts.
Reported by Georgia Pontikes, M.B.A.
Presence & Recognition
Amgen is sharing its latest advances in Thyroid Eye Disease at the European Thyroid Association's Annual Meeting.
Reported by Amgen
People
Amgen welcomed Courtney Grosslight to lead Global Marketing Excellence Training and Development.
Reported by Courtney Grosslight
People
Amgen has just posted new positions on the Cardiovascular Team.
Reported by Mark Elfers
Presence & Recognition
Amgen hosted the Innovation Inside Pharma conference in Rotkreuz
Reported by Simon P. Forster
Presence & Recognition
Amgen MSLs Portia Davis, Niaz Deyhim, Leslie Joseph, Lynell T. Wright, and Brendon Clough participated in a rheumatology update session with GCSHP members.
Reported by Portia Davis, PharmD
People
Amgen employee Pradeep Natarajan is sharing his perspective on the challenges of translating scientific hypotheses into medicines.
Reported by Pradeep Natarajan
Presence & Recognition
Amgen employee Sarah Khor spoke on behalf of the company at the IAPB event on rare diseases and the vision space.
Reported by Sarah Khor
Presence & Recognition
Amgen JAPAC and South Korea teams celebrated an important milestone for people living with thyroid eye disease (TED) in Seoul.
Reported by Sunil Mehta
Presence & Recognition
Amgen employee Amanda Beasley is participating in a partnership with Sites and DPHARM sessions.
Reported by Amanda Beasley, PhD (she/her)